Enhancement of Hypoxic Cell Sensitizer using a Vasodilator (Hydralazine)

概要

論文の詳細を見る
This experiment was undertaken to clarify whether or not hydralazine (HYD), a vasodilator, enhances the antitumor effect of the hypoxic cell sensitizers KU-2285,and misonidazole. HYD and both sensitizer were injected into the peritoneal cavity of C3H mice bearing either FM3A or the SCC VII tumor and radiotherapy was done by single irradiation of ^<60>CO (lO Gy). The marked decrease in tumor tissue blood flow following HYD injection was confirmed by laser doppler fluorometry and from the fluorescence or Hoechst-33342. In the untreated control group the mean quadrupling time of the FM3A tumor was 4.5 ± O.9 days and that of the SCC VII tumor was 7.8 ± 0.8 days.The results were 18.8 ± 5.4 days and 12.O ± 1.0 days respectively in the group subjected to radiation alone, 27.0 ± 3.8 days and 15.4 ± 1.4 days respectively in the group subjected to radiation followed by HYD administration, 24.6 ± 6.8 days and l3.4 ± 0.3 days respectively in the group subjected to KU-2285 administration combined with radiation and l5.O ± 1.9 days respectively in the group subjected to HYD administration after the same combined therapy that was done in the preceding group. These results indicate that HYD enhanced significantly the antitumor effect of radiotherapy performed either alone or in combination with the hypoxic cell sensitizer. In summary, the efficacy of either single radiotherapy or a combination of radiotherapy and hypoxic cell sensitizer was promoted by the subsequent administration of HYD. If the side effect of this vasodilator could be well controlled its clinical application would be possible as a useful adjuvant therapy.
鈴鹿医療科学大学の論文
1994-05-01

Enhancement of Hypoxic Cell Sensitizer using a Vasodilator (Hydralazine)

スポンサーリンク

概要

著者

関連論文

スポンサーリンク